title: Cognitive performance and the thymus among HIV-infected subjects receiving HAART.
abstract: OBJECTIVE
  To evaluate the impact of alcohol use, which is widespread in human immunodeficiency virus (HIV)+ individuals, on highly active antiretroviral therapy (HAART)-associated immune and cognitive improvements and the relationship between those two responses.
  
  
  METHODS
  In a case-control longitudinal study, thymic volume, cognition, and immune responses were evaluated at baseline and after 6 months therapy in HIV+ and HIV- controls. Cognitive performance was evaluated using the HIV Dementia Score (HDS) and the California Verbal Learning Test (CVLT).
  
  
  RESULTS
  Prior to HAART, thymic volume varied considerably from 2.7 to 29.3 cm(3) (11 +/- 7.2 cm(3)). Thymic volume at baseline showed a significantly inverse correlation with the patient's number of years of drinking (r(2) = 0.207; p < 0.01), as well as HDS and the CVLT scores in both HIV-infected (r(2) = 0.37, p = 0.03) and noninfected (r(2) = 0.8, p < 0.01). HIV-infected individuals with a small thymic volume scored in the demented range, as compared with those with a larger thymus (7 +/- 2.7 vs. 12 +/- 2.3, p = 0.005). After HAART, light/moderate drinkers exhibited thymus size twice that of heavy drinkers (14.8 +/- 10.4 vs. 6.9 +/- 3.3 cm(3)).
  
  
  CONCLUSIONS
  HAART-associated increases of thymus volume appear to be negatively affected by alcohol consumption and significantly related to their cognitive status. This result could have important clinical implications.
authors.affiliation: Robert Stempel School of public Health & School of Medicine, Florida International University, Miami, FL, USA.
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Miguez-Burbano
authors.forename: John E
authors.initials: JE
authors.lastname: Lewis
authors.forename: Jose
authors.initials: J
authors.lastname: Moreno
authors.forename: Joel
authors.initials: J
authors.lastname: Fishman
references.citation: Brain Res. 1994 Sep 26;658(1-2):127-34
references.pmid: 7834333
references.citation: Radiology. 1986 Feb;158(2):313-7
references.pmid: 3941858
references.citation: J Neuroimmunol. 1998 Feb;82(1):64-72
references.pmid: 9526847
references.citation: Endocr Rev. 2000 Aug;21(4):412-43
references.pmid: 10950159
references.citation: Am Clin Lab. 2001 Aug;20(7):13-6
references.pmid: 11570268
references.citation: J Endocrinol. 1995 Oct;147(1):5-10
references.pmid: 7490536
references.citation: Ann Neurol. 1986 Apr;19(4):349-55
references.pmid: 3085577
references.citation: AIDS Read. 2002 Feb;12(2):69-74
references.pmid: 11905143
references.citation: Alcohol Clin Exp Res. 1993 Jun;17(3):623-30
references.pmid: 8333593
references.citation: Alcohol. 1997 Jan-Feb;14(1):99-105
references.pmid: 9014030
references.citation: Cell Mol Biol (Noisy-le-grand). 2001 Feb;47(1):161-5
references.pmid: 11292251
references.citation: Behav Brain Res. 1997 Feb;83(1-2):63-9
references.pmid: 9062662
references.citation: Ann N Y Acad Sci. 1988;521:72-87
references.pmid: 3288046
references.citation: Lancet Neurol. 2005 Sep;4(9):543-55
references.pmid: 16109361
references.citation: Thymus. 1987;9(4):211-5
references.pmid: 3499687
references.citation: Neurol Res. 2005 Jan;27(1):41-6
references.pmid: 15829157
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):273-8
references.pmid: 7859139
references.citation: AIDS. 2001 Jan 26;15(2):195-200
references.pmid: 11216927
references.citation: Alcohol Res Health. 2001;25(4):288-98
references.pmid: 11910707
references.citation: Domest Anim Endocrinol. 2003 Jul;25(1):21-46
references.pmid: 12963097
references.citation: Alcohol Res Health. 2004-2005;28(2):57-62
references.pmid: 19006992
references.citation: Int J Dev Neurosci. 1997 Nov;15(7):911-20
references.pmid: 9568539